The Global Lifitegrast API Market is witnessing significant expansion due to the rising prevalence of Dry Eye Disease (DED) worldwide. The market was valued at US$ 124.5 Million in 2022 and is projected to reach US$ 198.7 Million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period (2024–2030). This growth is primarily driven by an aging global population, increased screen time leading to digital eye strain, and the growing adoption of advanced ophthalmic therapeutics.

As the pharmaceutical industry focuses on specialized active pharmaceutical ingredients (APIs) for targeted therapies, Lifitegrast stands out as a critical innovation for managing chronic dry eye. In this blog, we profile the Top 10 Companies in the Lifitegrast API Industry—a strategic mix of leading pharmaceutical manufacturers, specialized API producers, and innovators shaping the supply chain for this vital therapeutic ingredient.

Download FREE Sample Report:
Lifitegrast API Market – View in Detailed Research Report

---

🔟 1. Dr. Reddy’s Laboratories Ltd.

Headquarters: Hyderabad, Telangana, India
Key Offering: High-Purity Lifitegrast API (≥98%)

Dr. Reddy’s Laboratories is a globally recognized integrated pharmaceutical company with a strong API manufacturing division. The company has established itself as a reliable supplier of complex molecules, including Lifitegrast. Their expertise in process development and scale-up ensures consistent quality and supply for pharmaceutical customers worldwide.

Research & Development Initiatives:

• Advanced chemical synthesis and process optimization for complex APIs

• Robust regulatory expertise with multiple international certifications (USFDA, EMA)

• Sustainable manufacturing practices and continuous improvement in API production

---

9️⃣ 2. Gentec Pharmaceutical Group

Headquarters: Markham, Ontario, Canada
Key Offering: Lifitegrast API and Custom Synthesis Services

Gentec Pharmaceutical Group specializes in the development and manufacturing of high-potency APIs (HPAPIs) and complex molecules. The company offers a comprehensive portfolio, including contract research and manufacturing services (CRAMS) for pharmaceutical companies developing ophthalmic solutions.

Research & Development Initiatives:

• Focus on niche and difficult-to-synthesize small molecule APIs

• State-of-the-art analytical and quality control laboratories

---

8️⃣ 3. Teva API

Headquarters: Tel Aviv, Israel
Key Offering: Lifitegrast API, Generic APIs

Teva API, a division of Teva Pharmaceutical Industries Ltd., is one of the world’s largest producers of APIs. The company leverages its extensive manufacturing footprint and chemical synthesis capabilities to supply a broad range of APIs, including Lifitegrast, to the global pharmaceutical market, with a strong focus on quality and regulatory compliance.

Research & Development Initiatives:

• Investment in green chemistry and sustainable manufacturing processes

• Global supply chain resilience and multi-site manufacturing strategy

---

7️⃣ 4. Sun Pharmaceutical Industries Ltd.

Headquarters: Mumbai, Maharashtra, India
Key Offering: Lifitegrast API, Finished Dosage Forms

Sun Pharma is a leading international pharmaceutical company with a significant presence in the API market through its subsidiary, Sun Pharma Advanced Research Company (SPARC). The company’s vertically integrated model allows it to control the entire production process from raw materials to finished formulations, ensuring stringent quality control for APIs like Lifitegrast.

Research & Development Initiatives:

• Strong in-house R&D focused on process innovation and cost optimization

• Expansion of high-potency API (HPAPI) manufacturing capabilities

Download FREE Sample Report:
Lifitegrast API Market – View in Detailed Research Report

---

6️⃣ 5. Glenmark Pharmaceuticals

Headquarters: Mumbai, Maharashtra, India
Key Offering: Lifitegrast API and Specialty Chemicals

Glenmark Pharmaceuticals has a well-established API business with a focus on developing non-infringing processes for complex molecules. The company’s dedicated API R&D center works on novel synthetic routes, making it a competitive supplier of Lifitegrast API in regulated markets across North America, Europe, and Latin America.

Research & Development Initiatives:

• Proprietary technology platforms for efficient and scalable API synthesis

• Commitment to environmental, social, and governance (ESG) standards in manufacturing

---

5️⃣ 6. Olon Spa

Headquarters: Rodano, Milan, Italy
Key Offering: Contract Development and Manufacturing (CDMO) for Lifitegrast API

Olon Spa is a leading European-based CDMO with expertise in the production of highly potent and complex APIs. The company offers end-to-end services, from process development to commercial-scale manufacturing, serving the needs of innovators and generic companies in the ophthalmic space.

Research & Development Initiatives:

• Specialization in highly regulated markets with a strong quality management system

• Strategic focus on niche APIs and controlled substances

---

4️⃣ 7. ScinoPharm Taiwan, Ltd

Headquarters: Tainan, Taiwan
Key Offering: High-Purity Lifitegrast API, Oncology and Specialty APIs

ScinoPharm is a globally recognized API manufacturer with a strong foothold in the Asia-Pacific region. The company is known for its technical expertise in synthesizing complex molecules and maintaining high standards of purity and stability, making it a key player in the Lifitegrast API supply chain.

Research & Development Initiatives:

• Continuous investment in R&D to improve manufacturing yields and reduce costs

• Expansion of production capacity to meet growing global demand

---

3️⃣ 8. Hetero Drugs

Headquarters: Hyderabad, Telangana, India
Key Offering: Lifitegrast API, Antiretroviral and Oncology APIs

Hetero is one of India’s leading generic pharmaceutical companies with a robust API manufacturing vertical. The company’s strength lies in its vertically integrated operations and its ability to produce APIs at a competitive cost while adhering to international quality standards, serving a diverse global clientele.

Research & Development Initiatives:

• Focus on developing cost-effective and scalable manufacturing processes

• Strong regulatory filings and approvals in key global markets

---

2️⃣ 9. Aurobindo Pharma Ltd.

Headquarters: Hyderabad, Telangana, India
Key Offering: Lifitegrast API, Broad Portfolio of Generic APIs

Aurobindo Pharma has a significant presence in the API market through its subsidiary, Aurobindo Pharma USA Inc. The company’s API division focuses on developing non-infringing processes and has the manufacturing capability to support both its own formulations and supply to other pharmaceutical companies worldwide.

Research & Development Initiatives:

• Investment in new technology for API manufacturing and process automation

• Strategic partnerships to enhance global market access

---

1️⃣ 10. MSN Laboratories Pvt. Ltd.

Headquarters: Hyderabad, Telangana, India
Key Offering: Lifitegrast API, Custom Synthesis

MSN Laboratories is a rapidly growing pharmaceutical company with a dedicated focus on API research, development, and manufacturing. The company has built a reputation for delivering high-quality APIs with a commitment to innovation and customer-centric solutions, positioning it as a key emerging supplier in the Lifitegrast API market.

Research & Development Initiatives:

• Strong emphasis on developing novel, environmentally benign synthetic routes

• Expansion of regulatory capabilities to cater to developed markets

---

🔬 Outlook: The Future of Lifitegrast API Is Innovation and Accessibility

The Lifitegrast API market is undergoing a transformation driven by the increasing need for effective dry eye treatments and the impending patent expirations of branded formulations. The market’s future will be characterized by technological advancements in API synthesis, regulatory harmonization, and strategic partnerships.

📈 Key Trends Shaping the Market:

• Accelerated development of generic versions post-patent expiry, increasing market competition

• Rising investment in continuous manufacturing processes for improved efficiency and yield

• Growing demand from emerging economies with increasing healthcare awareness

• Strategic collaborations between API manufacturers and ophthalmic drug developers

Get Full Report Here:
Lifitegrast API Market – View in Detailed Research Report

The companies listed above are not only supplying a critical pharmaceutical ingredient—they’re enabling the global fight against chronic dry eye disease through innovation, quality, and reliability.